



# Alpha-Mannosidosis Sponsored Genetic *Testing* Program

GeneDx and Chiesi USA have partnered to provide eligible patients with suspected Alpha Mannosidosis access to genetic testing. Through this program, eligible patients can receive whole genome testing at no cost to them.

**Is your patient eligible? Patients must meet all of the following criteria:**

- ✓ Patient must reside in the USA or one of its territories
- ✓ Have developmental delay and TWO of the following: Coarse facial features, impaired mobility, recurring infections, hearing loss
- ✓ No prior genetic testing performed by clinical laboratory which explained patient's symptoms
- ✓ The ordering provider must be authorized under applicable laws to order genetic testing in the US

**From sample received to report in as soon as 4 weeks**

- Order is placed by healthcare provider
- Kit is shipped to patient
- Sample is collected and kit is shipped to GeneDx
- Sample is processed and results are analyzed
- Results are delivered to healthcare professional

## Your patient's data stays private

GeneDx will not share any personally identifiable patient information or raw sequencing data with Chiesi or with other biopharma industry partners.

# How to order

- 1 Login or sign up for a GeneDx account and add 1 of the following tests to your cart:
  - GenomeDx™, proband
  - GenomeDx™, duo
  - GenomeDx™, trio
- 2 Select the program code STP - AM
- 3 Confirm your patient's eligibility
- 4 Follow the prompts and enter in the appropriate information
- 5 Place your order and GeneDx will follow up when your results are ready



Ordering also available  
via paper program TRF

For access to the program-specific TRF, please scan the QR code or visit [genedx.com/providers/genetic-testing-programs/alpha-mannosidosis](https://genedx.com/providers/genetic-testing-programs/alpha-mannosidosis)

## Find answers with genome sequencing

Genome sequencing provides the most complete picture of an individual's DNA, detecting variants across coding and non-coding regions as well as structural changes missed by other methods. This comprehensive view increases the chance of finding meaningful answers in complex, atypical, or undiagnosed cases. GenomeDx™ clinical genome sequencing is performed at  $\geq 40\times$  average coverage across the genome (minimum  $30\times$ ), with  $\sim 97\%$  of coding regions assessed at  $\geq 15\times$  coverage. Analysis includes SNVs, CNVs  $>1$  kb, select repeat expansions, SMN1 exon 8 loss, and uniparental disomy (when parents are submitted). All testing is performed in GeneDx's CLIA-certified and CAP-accredited laboratory.



Remove barriers to testing.  
Empower earlier insights.

Images are illustrative only and not actual patients

© 2026 GeneDx, LLC. 205 & 207 Perry Parkway, Gaithersburg, MD 20877. All Rights Reserved. GeneDx.com | Alphascreen: PP-RA-01809 v1.0 | February 2026

GeneDx®

Chiesi  
global rare diseases